Last reviewed · How we verify
NCT06612736
Nutritional Management of Neurologically Impaired Children Across China
trial in Neurological Impairments in 586 participants. Completed in 1 May 2023.
1 January 2023
Quick facts
| Lead sponsor | Shanghai Jiao Tong University School of Medicine |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 586 |
| Start date | 6 December 2021 |
| Primary completion | 1 January 2023 |
| Estimated completion | 1 May 2023 |
| Sites | 1 location across China |
Conditions studied
- Neurological Impairments — all drugs for Neurological Impairments →
Sponsor
Shanghai Jiao Tong University School of Medicine
Who can join
Under 18, any sex, with Neurological Impairments. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A retrospective study to (1) investigate clinical characteristics, nutritional status, and nutritional management in neurologically impaired children in China, (2) assess whether enteral nutrition (particularly tube feeding) contributes to improving nutritional outcomes in children with neurological impairments, (3) examine the tolerability of enteral nutrition and whether it can effectively reverse or prevent severe malnutrition.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06612736
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neurological Impairments
Currently open trials in the same condition.
- NCT06666777 — Speech Therapy and Parenting for Early Socio-communicAtive sKills · NA · recruiting
Other Shanghai Jiao Tong University School of Medicine trials
Trials by the same sponsor.
- NCT07570810 — Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM · NA · not yet recruiting
- NCT07528079 — Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors · NA · enrolling by invitation
- NCT07535710 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-ce · Phase 1, PHASE2 · not yet recruiting
- NCT07535762 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T · Phase 2 · not yet recruiting
- NCT07350057 — A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graf · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06612736 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Jiao Tong University School of Medicine
- Last refreshed: 25 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06612736.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing